Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Superior safety of dual therapy with dabigatran and clopidogrel vs. triple therapy with warfarin, aspirin and clopidogrel in the RE-DUAL PCI trial: What is key, the strategy or the drug?

Published:2017-12 Issue: Volume:46 Page:e40-e41
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Rubboli Andrea

Publisher

Elsevier BV

Subject

Internal Medicine

Reference6 articles.

1. Prevention of bleeding in patients with atrial fibrillation undergoing PCI;Gibson;N Engl J Med,2016

2. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation;Cannon;N Engl J Med,2017

3. Dabigatran versus warfarin in patients with atrial fibrillation;Connolly;N Engl J Med,2009

4. Apixaban versus warfarin in patients with atrial fibrillation;Granger;N Engl J Med,2011

5. Edoxaban versus warfarin in patients with atrial fibrillation;Giugliano;N Engl J Med,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gray zones on dual antiplatelet therapy. Expert opinions;G ITAL CARDIOL;2020

2. Warfarin therapy in Chinese patients with atrial fibrillation treated with percutaneous coronary intervention: a 5 year follow-up retrospective cohort study;Current Medical Research and Opinion;2019-07-09

3. And now we have the AUGUSTUS … How will it impact on antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?;European Journal of Internal Medicine;2019-07

4. The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly;Frontiers in Physiology;2018-07-09

5. What is the significance, if any, of the increased incidence of stent thrombosis with dual therapy of dabigatran 110 mg twice daily and clopidogrel in the RE-DUAL PCI trial?;European Journal of Internal Medicine;2018-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3